

Title (en)
ANTI-CANCER VACCINES

Title (de)
IMPFSTOFFE GEGEN KREBS

Title (fr)
VACCINS ANTICANCER

Publication
EP 1660636 A2 20060531 (EN)

Application
EP 04782297 A 20040826

Priority
• US 2004027790 W 20040826
• US 49823803 P 20030826

Abstract (en)
[origin: WO2005019435A2] The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.

IPC 1-7
C12N 1/00

IPC 8 full level
A61K 39/00 (2006.01); **A61P 35/02** (2006.01); **C07K 14/00** (2006.01); **C12N 5/07** (2010.01); **C12N 5/077** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/0786** (2010.01); **C12N 5/09** (2010.01)

IPC 8 main group level
C12N (2006.01)

CPC (source: EP US)
A61K 39/001158 (2018.08 - EP US); **A61K 39/4611** (2023.05 - EP US); **A61K 39/4621** (2023.05 - EP US); **A61K 39/46434** (2023.05 - EP US); **A61K 39/464458** (2023.05 - EP US); **A61K 2239/38** (2023.05 - US); **A61K 2239/48** (2023.05 - US); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **C07K 14/4748** (2013.01 - EP); **A61K 2239/38** (2023.05 - EP); **A61K 2239/48** (2023.05 - EP)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2005019435 A2 20050303; **WO 2005019435 A3 20060629**; **WO 2005019435 A8 20060427**; AU 2004267506 A1 20050303; CA 2536654 A1 20050303; EP 1660636 A2 20060531; EP 1660636 A4 20090701; EP 1670899 A2 20060621; JP 2007504149 A 20070301; WO 2005035714 A2 20050421; WO 2005035714 A3 20090416

DOCDB simple family (application)
US 2004027790 W 20040826; AU 2004267506 A 20040826; CA 2536654 A 20040826; EP 04782297 A 20040826; EP 04809624 A 20040826; JP 2006524856 A 20040826; US 2004027792 W 20040826